|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Pipeline Insight: HIV - The Age of Convenience
|
| Published Date:
October 2009
Published By:
Datamonitor
Page Count:
180
Order Code:
R313-55079
|
|
|
|
Introduction
Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naοve patients. Addressing Atripla's shortcomings, Datamonitor expects this product to dominate the market.
Scope- In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs
- An overview of the key companies involved in the HIV pipeline, including an analysis of the new corporate alliances
- The epidemiology dynamics of HIV in the six major markets are discussed along with unmet needs that have evolved from the prolonged use of HAART
- Sales forecasts over the next 10 years for the each of the late-stage drugs
Highlights
Advances in antiretroviral therapy have addressed the two big unmet medical needs, resistance and safety. Convenience is the new frontier, pointing towards a bright future for cross-class fixed-dose combination, notably Gilead's Quad Pill and Gilead's and Johnson & Johnson's Truvada/rilpivirine combination.
Gilead's two new cross-class fixed dose combinations offer only moderate medical progress, but their added convenience compared with single ingredient formulations will cement the company's market leadership and reduce the market opportunity for single-ingredient formulations.
Abbott's monopoly in protease inhibitor boosting agents is nearing its end. At least three companies have pharmacokinetic enhancers with potentially improved safety profiles in clinical development, hopefully enabling the creation of more co-formulated brands
Reasons to Purchase- Understand the constantly evolving market dynamics of antiretroviral drugs in view of corporate alliances, co-formulations and generic entry
- Learn about the changing unmet needs of patients and the extent to which pipeline drugs are addressing these issues
- Evaluate the forecast of key pipeline antiretroviral drugs to 2018, taking into account key launch dates, patent expirations and other factors
Please note: this is delivered as a Zip file.
|
Similar Products
Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
